Overview of Seroflo Rotacap 250 mcg Research Applications
Seroflo Rotacap 250 mcg is a combination respiratory pharmaceutical manufactured by Cipla, containing both salmeterol xinafoate and fluticasone propionate in a dry powder inhaler format. This dual-action formulation represents an important research tool for investigating bronchodilator and anti-inflammatory mechanisms in respiratory models. Researchers examining Stroid UK Shop frequently utilise this preparation to study the synergistic effects of long-acting beta-2 agonists combined with corticosteroids in preclinical respiratory research protocols.
Pharmacological Research Parameters
The active pharmaceutical ingredients in Seroflo demonstrate distinct mechanisms of action valuable for respiratory research. Salmeterol functions as a long-acting beta-2 adrenergic receptor agonist, promoting bronchodilation through cyclic adenosine monophosphate pathways, while fluticasone propionate acts as a potent synthetic corticosteroid with anti-inflammatory properties. Research teams investigating pharmaceutical compounds analyse how this combination modulates airway smooth muscle relaxation and inflammatory mediator suppression in controlled laboratory environments. Studies examine the pharmacokinetic profiles, receptor binding affinities, and dose-response relationships of both components in various experimental models. Advanced researchers also investigate the compound’s effects on cytokine expression, eosinophil recruitment, and mucus hypersecretion patterns. The rotacap delivery system enables precise dosing studies comparing different inhalation techniques and particle deposition patterns. Scientists studying selective research compounds often compare the tissue selectivity and systemic exposure profiles of inhaled versus systemic administration routes.
Technical Specifications
| Parameter | Specification |
|---|---|
| Manufacturer | Cipla Limited |
| Formulation | Dry powder inhaler capsules |
| Active Ingredients | Salmeterol xinafoate + Fluticasone propionate |
| Strength | 250 mcg combination dose |
| Delivery System | Rotacap inhalation device |
| Storage Requirements | Store below 25°C, protect from moisture |
| Research Applications | Respiratory pharmacology, inhalation studies |
Quality control protocols verify the consistent particle size distribution and drug content uniformity essential for reproducible research outcomes. Researchers examining bioactive compounds appreciate the standardised manufacturing processes ensuring batch-to-batch consistency in experimental applications.
Laboratory Research Compliance
This product is supplied exclusively for in-vitro laboratory research applications and must not be used for human consumption, therapeutic purposes, or any form of clinical application. Researchers must maintain appropriate laboratory safety protocols and institutional approval for all experimental procedures involving this pharmaceutical preparation.
